Targeting Tumors from the Inside Out

Episode Summary

Executive Summary: The episode features Nanology’s Mark Jacobucci describing a platform that converts existing oncology drugs into large-surface-area microparticles for intratumoral delivery. The goal is to keep drugs concentrated inside tumors longer, improve tumor kill and immune priming, reduce systemic toxicity, and create a path to late-stage development and partnering.

Main Topics: Why systemic chemotherapy is limited (Priority: 5/5): Jacobucci explains that standard chemotherapy remains central to cancer care but often causes dose-limiting off-target toxicity, including nausea, immune suppression, and organ damage, which can force treatment discontinuation. Intratumoral delivery as an alternative (Priority: 5/5): The conversation outlines how direct delivery into or around tumors can create high local drug concentrations, prolonged retention, and potentially better tumor control with less systemic exposure. Nanology’s precision particle engineering platform (Priority: 5/5): Nanology’s technology transforms existing drugs into microparticles optimized for intratumoral retention and release, with a focus on maintaining particle size while increasing surface area for sustained local dosing. Evidence across multiple drug classes and cancers (Priority: 4/5): The company says its platform has been applied to small molecules, large molecules, and immunotherapy agents, with studies in several solid tumors and clinical signs of safety, response, and immune modulation. Clinical development and partnering strategy (Priority: 4/5): Nanology has completed multiple early-stage trials and is now aiming for randomized late-phase studies, while actively seeking pharma partners and outside capital to advance assets. Market dynamics and shifting sentiment (Priority: 3/5): Jacobucci argues that interest in intratumoral therapy is rising as the field seeks rational combinations that improve efficacy without stacking toxicity, making the approach more attractive to pharma.

Key Arguments: Systemic chemotherapy is effective but inherently toxic because it exposes normal tissues as well as cancer cells, limiting dose and benefit. Intratumoral delivery can reduce toxicity by keeping drug localized while sustaining high concentrations inside the tumor. The main technical challenge is not just getting drug into a tumor, but keeping it there long enough to matter. Nanology’s platform is designed to preserve large particle size for retention while increasing surface area for controlled release. The technology appears applicable across multiple classes of oncology drugs, especially hydrophobic small molecules. Preclinical and clinical data suggest repeated injections may improve outcomes by addressing tumor heterogeneity. LSAM paclitaxel and related assets have shown safety and early signals of efficacy, including anti-tumor immunomodulation. The company believes intratumoral therapy may become increasingly important as combination oncology regimens continue to be constrained by toxicity. Nanology is pursuing partnerships because late-stage development will likely require external pharma collaboration and additional capital.

Data Points: Clinical trials completed across lead assets: 7 single-arm trials - Nanology says it has completed seven single-arm phase 1/2 studies across LSAM paclitaxel and LSAM docetaxel. Patients treated with LSAM paclitaxel: >140 patients - Across six clinical trials of LSAM paclitaxel, the company reports treating more than 140 patients. Microparticle size: 2 to 3 microns - The platform’s particles are described as microparticles sized to be retained in the tumor. Drug retention duration: Up to 4 weeks - Preclinical and clinical data are said to show drug remaining in tumor over four weeks, depending on drug class. Partner contacts tracked: >100 contacts - The company says it has established contact with more than 100 pharma contacts over the last four years. Active confidential partner discussions: 8 pharma partners - Nanology reports ongoing confidential discussions with eight potential pharma partners. Planned external capital raise: Late 2026 - The company plans a capital raise in late 2026 to potentially advance an indication independently. Sponsored conference timing: February 11-12, 2026 - Sponsor mention referenced the 18th Annual Outsourcing and Clinical Trials West Coast conference.

Pivotal Quotes: "Chemotherapy, these are extremely potent compounds that are toxic to all cells, cancer cells, and normal tissue as well." — Mark Jacobucci: Explaining the core limitation of systemic chemotherapy and why toxicity constrains treatment. "What we are trying to do is to provide the immune, the debulking of the primary tumor plus immune primate to increase the response to IO, which our data suggests, and do that without increasing toxicity." — Mark Jacobucci: Describing Nanology’s value proposition for combining local tumor control with immune activation. "Our drug stays put." — Mark Jacobucci: Summarizing the platform’s main claim: localized retention and prolonged release inside tumors.

Implications: If validated in randomized trials, intratumoral microparticle delivery could broaden use of existing oncology drugs, improve immunotherapy combinations, and reduce systemic side effects, making the approach attractive to pharma and clinicians.